Table 1 Methylation and mutation profile of NSCLC
Clinical characteristics (cases) | Methylation (%) | EGFR mutation (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Â | SFRP1 | SFRP2 | SFRP5 | DKK3 | WIF1 | APC | CDH1 | Any gene | Â |
Gender | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Male (74) | 30 (40.5) | 20 (27.0) | 9 (12.2) | 9 (12.2) | 3 (4.1) | 13 (17.6) | 7 (9.5) | 44 (59.5) | 36 (48.6) |
Female (81) | 31 (38.3) | 20 (24.7) | 14 (17.3) | 13 (16.0) | 3 (3.7) | 18 (22.2) | 8 (9.9) | 48 (59.3) | 49 (60.5) |
Age | Â | Â | Â | Â | Â | Â | Â | Â | Â |
<65 (89) | 33 (37.1) | 21 (23.6) | 10 (11.2) | 12 (13.5) | 3 (3.4) | 16 (18.0) | 7 (7.9) | 48 (53.9) | 56 (62.9)* |
≥65 (66) | 28 (42.4) | 19 (28.8) | 13 (19.7) | 10 (15.2) | 3 (4.5) | 15 (22.7) | 8 (12.1) | 44 (66.7) | 29 (43.9) |
Smoking | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Never (93) | 35 (37.6) | 24 (25.8) | 14 (15.1) | 15 (16.1) | 2 (2.2) | 21 (22.6) | 8 (8.6) | 58 (62.4) | 57 (61.3)* |
Smokers (62) | 26 (41.9) | 16 (25.8) | 9 (14.5) | 7 (11.3) | 4 (6.5) | 10 (16.1) | 7 (11.3) | 34 (54.8) | 28 (45.2) |
Histology | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Adenocarcinoma (118) | 46 (38.9) | 30 (25.4) | 16 (13.6) | 16 (13.6) | 4 (3.4) | 21 (17.8) | 14 (11.9) | 72 (61.0) | 65 (55.1) |
Non-adenocarcinoma (37) | 15 (40.5) | 10 (27.0) | 7 (18.9) | 6 (16.2) | 2 (5.4) | 7 (18.9) | 1 (2.7) | 20 (54.1) | 20 (54.1) |
Total | 61 (39.4) | 40 (25.8) | 23 (14.8) | 22 (14.2) | 6 (38.7) | 31 (20%) | 15 (9.7%) | 92 (59.4%) | 85 (54.8%) |